我們已在上線！進一步了解

Altimmune

ALT

市值 US$4.28億

2.20 USD

-0.16

6.78%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

2.22

+0.02

0.91%

1天

-6.78%

5天

-15.06%

1個月

-32.1%

3個月

-22.81%

6個月

-37.32%

今年迄今

-37.32%

1年

-43.44%

5年

-81.97%

10年

-99.74%

關於： Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

員工： 57

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 23.5%

中性 70.6%

負面 5.9%

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

Altimmune to Participate in Stifel Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.

Altimmune to Participate in Stifel Cardiometabolic Forum

Zacks Investment Research

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Zacks Investment Research

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Zacks Investment Research

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.

Altimmune Q2 Earnings Call Highlights

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

查看新聞排名

價格圖表採用Lightweight Charts™實作